Table 1 COVID-19 vaccine breakthrough cases reported to CDC from five U.S. states during January–March 2021
Characteristic | Vaccine breakthrough cases [N = 1582] | |
|---|---|---|
No | (%) | |
Gender | ||
Female | 1053 | (67) |
Male | 524 | (33) |
Unknown | 5 | (< 1) |
Age group in years | ||
16–49 | 632 | (40) |
50–64 | 333 | (21) |
65–74 | 226 | (14) |
75–84 | 235 | (15) |
≥ 85 | 156 | (10) |
Race/ethnicity | ||
Non-Hispanic | ||
White | 1024 | (65) |
Black | 60 | (4) |
American Indian/Alaska Native | 52 | (3) |
Asian | 24 | (2) |
Multiracial/other | 50 | (3) |
Hispanic, any race | 75 | (5) |
Unknown | 297 | (19) |
Residence type | ||
Long-term care facility | 227 | (14) |
Other | 956 | (60) |
Unknown | 399 | (25) |
Positive SARS-CoV-2 test type | ||
Nucleic acid amplification test | 1312 | (83) |
Antigen | 254 | (16) |
Unknown | 16 | (1) |
Vaccine received | ||
Pfizer-BioNTech | 1073 | (68) |
Moderna | 502 | (32) |
Unknown | 7 | (< 1) |
Symptoms associated with positive test | ||
Asymptomatic | 531 | (34) |
Symptomatic | 661 | (41) |
Unknown | 390 | (25) |
Hospitalized | ||
Yes† | 181 | (11) |
Outcome | ||
Died‡ | 42 | (3) |